Sanofi S.A. Stock
€86.90
Your prediction
Sanofi S.A. Stock
Pros and Cons of Sanofi S.A. in the next few years
Pros
Cons
Performance of Sanofi S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sanofi S.A. | -0.150% | -6.074% | -11.399% | -3.680% | -7.128% | -13.308% | -1.663% |
| Ipsen S.A. | -1.520% | 1.162% | 0.096% | -14.133% | -5.344% | 10.758% | 47.183% |
| Johnson & Johnson | -1.020% | -0.563% | -2.752% | -1.148% | -3.451% | -18.401% | 3.675% |
| Elanco Animal Health Inc. | -0.270% | 1.393% | 36.616% | -29.536% | 2.096% | -47.981% | -40.754% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.The financials of Snof, a notable player in the pharmaceuticals industry under the US symbol, reveal a company that is navigating the complexities of the market with a significant degree of stability. At first glance, the metrics suggest that Snof is maintaining a solid financial position, showcasing steady revenue growth and robust earnings, while also investing heavily in research and development. However, a deeper dive into specific figures illustrates both strengths and weaknesses that can help shape expectations for potential investors or stakeholders.
Strong Revenue Generation: For the fiscal year ending December 31, 2023, Snof reported total revenues of approximately €43.07 billion. This sizable revenue indicates robust demand for its pharmaceutical products and the effectiveness of its sales strategy, especially considering the revenue reflected a continued upward trend from previous years.
Solid Profit Margins: The profit margin stands at approximately 8.95%, which suggests that Snof is not only generating revenue but also retaining a healthy portion as profit. This profitability is further emphasized by a stable operating margin of 14.11%, making it clear that operational efficiency is being managed well.
Comments
News
Sanofi Stock: $9.1 Billion Blueprint Deal Sparks Debate
The French pharmaceutical giant Sanofi has announced plans to acquire US-based Blueprint Medicines for $9.1 billion, marking a strategic push into the specialized immunology market. The ambitious
Sanofi Stock: Setback in Lung Drug Trial Hits Shares
The French pharmaceutical giant Sanofi faced a significant blow as its lung medication candidate Itepekimab delivered mixed Phase III trial results. While one of the critical studies showed the drug
Sanofi Stock: $600M Alzheimer Drug Acquisition Bet
Sanofi has made a strategic move to strengthen its neurology portfolio by acquiring Vigil Neuroscience for up to $600 million. The French pharmaceutical giant will pay $470 million ($8 per share)